Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma

There are only limited treatment options for metastatic NRAS mutant melanoma patients with resistance to immune checkpoint inhibitors. Besides activation of the mitogen-activated protein (MAP) kinase pathway, they often have additional disturbances in cell cycle regulation. However, unlike BRAF muta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Autores principales: Forschner, Andrea, Sinnberg, Tobias, Mroz, Gabi, Schroeder, Christopher, Reinert, Christian Philipp, Gatidis, Sergios, Bitzer, Michael, Eigentler, Thomas, Garbe, Claus, Niessner, Heike, Röcken, Martin, Roggia, Cristiana, Armeanu-Ebinger, Sorin, Riess, Olaf, Mattern, Sven, Nann, Dominik, Bonzheim, Irina
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7959243/
https://ncbi.nlm.nih.gov/pubmed/33732653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.643156
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares